Cargando…
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
Huntington disease (HD) is a dominantly inherited progressive neurological disease characterized by chorea, an involuntary brief movement that tends to flow between body regions. HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic...
Autor principal: | Frank, Samuel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951749/ https://www.ncbi.nlm.nih.gov/pubmed/20957126 http://dx.doi.org/10.2147/NDT.S6430 |
Ejemplares similares
-
Correction:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study
por: Frank, Samuel
Publicado: (2011) -
Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
por: Frank, Samuel
Publicado: (2009) -
Tetrabenazine in the treatment of Huntington’s disease
por: Paleacu, Diana
Publicado: (2007) -
Management of Huntington’s disease: role of tetrabenazine
por: de Tommaso, Marina, et al.
Publicado: (2011) -
Tetrabenazine is neuroprotective in Huntington's disease mice
por: Wang, Hongyu, et al.
Publicado: (2010)